קלנג שמואל, ד”ר
Background
Progressive leadership experience in large healthcare organizations from pharmacy operations oversight to strategic planning, business development, reimbursement, technology assessment and supply chain optimization.
Successful track record in developing new programs and services from conceptualization to launch.
Employment History
Meuhedet Health Service 2018-Present
Meuhedet Health Services is Israel’s third largest HMO having 1.2 million people insured.
Director of Pharmaceutical Policy and Medical Technologies Division
- Directing operations staff responsible for pre-authorization of drugs, procedures and medical equipment.
- Represents Meuhedet in the National Health Basket Committee (national Reimbursement law)
- Directing Health technology assessment staff including Institutional Drug committee and Institutional Medical devices and technologies committee.
- Head of Pharmacology and Pharmaco-economics, from models to implementation
Director of the Meuhedet Institute for Health Services Research
The missions of Meuhedet Institute for Health Science Research:
- To provide an organizational framework which encourages and supports health services research in the environment of a healthcare organization with the goal of furthering the health and well-being of its members.
- To conduct research that can be translated into clinical practice, health promotion, and policies to influence the health of individuals and populations
Clalit Health Services – CHS
Clalit Health Services is Israel’s largest and the world’s second largest HMO having 4.2 million people insured.
Head of Pharmacy and Pharmacology 2002 – 2018
- Formulates CHS’ Annual Drug Policy and budget worth billions of NIS
- Represents the CHS’ in the National Health Basket Committee (national Reimbursement law)
- Orchestrates CHS’ collaboration with multinational Pharma and MedTech companies in the areas of R&D, clinical trials and joint programs
- Directing CHS’ national Pharmacy Operations staff of 1,100 community and hospital pharmacist, 450 pharmacies and 70M prescriptions annually
- Initiated CHS’ pioneering Personalized Medicine (Oncogenetics and Individualized antiplatelet therapy) strategy and programs
- Developed and implemented prescriber support processes that assure quality therapeutic & cost effective decision-making.
- Promoted to lead drug adherence research in CHS’ pharmacy operations Israeli Ministry of Health (MoH)
Israeli Ministry of Health (MoH)
Senior Assistant to the Head of Pharmacy 1998-2000
- Evaluated clinical outcomes and cost-efficacy of new drugs and medical technologies submitted for reimbursement to the National Health Basket.
- Initiated and implemented restructuring of the MoH’s Pharmaceutical Division
- Presented the professional opinion of MoH Pharmaceutical Division in the Knesset (Israeli Parliament).
Lecture Oct. 2015-2018
- The Hebrew University of Jerusalem, The Faculty of Medicine, School of Pharmacy
Research
Publications
- H. Klang, J. Frucht-Pery, A. Hoffman, and S. Benita. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J. Pharm. Pharmacol. 46:986-993, 1994 .
- H. Klang, Baszkin A., and S. Benita. The stability of piroxicam incorporated in a positively-charged submicron emulsion for ocular administration. Int. J. Pharm. 132;33-44, 1996 .
- KLANG SH; SIGANOS CS; BENITA S; FRUCHTPERY J. PIROXICAM POSITIVELY-CHARGED EMULSION PROTECTS AGAINST CORNEAL ALKALIBURN IN A RABBIT MODEL. Investigative ophthalmology & visual science. issue: 3, vol. 3 : 364 – 364, 1996.
- H. Klang, M. Parnas and S. Benita. Emulsions as drug carriers-possibilities, limitations and future perspectives. In: Emulsions and nanosuspensions for the formulation of poorly soluble drugs. R.H. Muller, S. Benita and B. Bohm eds., Medpharm scientific publishers, Stuttgart. . 1998.
- H. Klang and S. Benita. Design and evaluation of submicron emulsions as colloidal drug carriers for intravenous administration. In: Submicron emulsions in drug targeting and delivery. S. Benita ed., Harwood academic publishers, The Netherlands. 1999.
- H. Klang, C.S. Siganos, S. Benita, and J. Frucht-Pery.. Evaluation of a positively- charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn. J. Control. Rel. 57:19-27, 1999.
- BenEzra, S.H. Klang, G. Maftzir, and S. Benita. Submicron emulsions and their effect on corneal cells in vitro. (Submitted for publication)
- H. Klang, G. Slama, I. Ringel, A. Kaplun, Y. Talmon and S. Benita. The microstructure of a positively-charged submicron emulsion emulsion. (Submitted for publication).
- Klang S, Abdulrazik M., and Benita S. indomethacin ocular tissue distribution. Influence of emulsion droplet surface charge on Pharm Dev Technol. 5(4):521-32, 2000 .
- Klang S., Lieberman N., Porath A., Peterburg Y. Reimbursed drug regulation: Comparing two models for control drugs consumption in Israel using permeation coefficient parameter. The Third Annual European Conference of the International Society for Pharmacoeconomics and Outcome Research (ISPOR), November 2000, Antwerp, Belgium.
- Giveon S.M., Liberman N., Klang S., Kahan E. Are people who use “natural drugs” aware of their potentially harmful side effects and reporting to family physician? Patient Education and Counseling 53, 5-11, 2004
- Ariel Hammerman, Jacob Dreiher, Shmuel H. Klang, Hanan Munitz, Arnon D. Cohen and Margalit
Goldfracht. Antipsychotics and diabetes: an age-related association study.Annals of Pharmacotherapy 42: 1316-1322, : 2008.
- Zohar Levi , MD , Paul Rozen, Rachel Hazazi, Alex Vilkin , Amal Waked , Eran Maoz , Shlomo Birkenfeld , Nicky Lieberman, Shmuel Klang , Yaron Niv. Sensitivity, but not Specificity of a Quantitative Immunochemical Fecal Occult Blood for Neoplasia, is Slightly Increased by Low Dose Aspirin, NSAIDS and Anti Coagulants Use. The American Journal of GASTROENTEROLOGY, 17 March 2009.
- A Hammerman, SH Klang, N Liebermann. REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS— A COMPARATIVE ANALYSIS. Value in Health, Vol. 12, Issue 7, A260 October, 2009
- 15. Nitzan, M. Low, I. Lavi, A. Hammerman, S. Klang, R. Raz. Variability in Outpatient Antimicrobial Consumption in Israel. Infection 2010; 38: 12–18
- Shmuel H. Klang, PhD, Ariel Hammerman, PhD, Nicky Liebermann, MD, Noa Efrat, MD, Julie Doberne, BS, John Hornberger, MD. Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization. Value In Health 13 (4), 337–508 , 15 APR 2010
- Stemmer, SM; Klang, SH; Ben-Baruch, N; Geffen, DB; Steiner, M; Soussan-Gutman, L; Merling, S; Svedman, C; Rizel, S; Lieberman, N. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat. Jul; 140(1): 83–92, 2013.
18. Klang, Shmuel H. a; Ben-Amnon, Yuval b; Cohen, Yaeli a; Barak, Yoram. Community pharmacists’ support improves antidepressant
adherence in the community. Int Clin Psychopharmacol. 2015 Nov;30(6):316-9.
19. Clinical Outcomes in Patients with Node-negative Breast Cancer Treated Based on the Recurrence Score Results: Evidence from a Large
Prospectively-designed Registry” by Salomon Stemmer, Mariana Steiner, Shulamith Rizel, Lior Soussan-Gutman, Noa Ben Baruch, Avital
Bareket-Samish, David Geffen, Bella Nisenbaum, Kevin Isaacs, Georgeta Fried, Ora Rosengarten, Beatrice Uziely, Christer Svedmann,
Debbie McCullough, Tara Maddala, Shmuel Klang, Jamal Zidan, Larisa Ryvo, Bella Kaufman, Ella Evron, Natalya Karminsky, Hadassah
Goldberg, Steven Shak, and Nicky Liebermann. npj Breast Cancer In press
